Thus, a combination of mutated NPM1 and non-mutated FLT3/Internal tandem duplication (FLT3/ITD) associates with favorable outcome in IR-AML patients [7,8,9,10]. This evidence concerns the gene FLT3 and acute myeloid leukemia.